Immunovia Financial Statements From 2010 to 2025
| IMMVF Stock | USD 0.05 0.00 0.00% |
Check Immunovia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovia's main balance sheet or income statement drivers, such as , as well as many indicators such as . Immunovia financial statements analysis is a perfect complement when working with Immunovia Valuation or Volatility modules.
Immunovia |
Immunovia AB Company Current Valuation Analysis
Immunovia's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunovia Current Valuation | 51.96 M |
Most of Immunovia's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunovia AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunovia AB has a Current Valuation of 51.96 M. This is 99.64% lower than that of the Healthcare sector and 99.33% lower than that of the Diagnostics & Research industry. The current valuation for all United States stocks is 99.69% higher than that of the company.
Immunovia AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunovia's current stock value. Our valuation model uses many indicators to compare Immunovia value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunovia competition to find correlations between indicators driving Immunovia's intrinsic value. More Info.Immunovia AB is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunovia's earnings, one of the primary drivers of an investment's value.About Immunovia Financial Statements
Immunovia stakeholders use historical fundamental indicators, such as Immunovia's revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunovia investors may analyze each financial statement separately, they are all interrelated. For example, changes in Immunovia's assets and liabilities are reflected in the revenues and expenses on Immunovia's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Immunovia AB. Please read more on our technical analysis and fundamental analysis pages.
Immunovia AB , a diagnostic company, develops and commercializes blood tests in Sweden and internationally. Immunovia AB was incorporated in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 69 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Immunovia Pink Sheet
Immunovia financial ratios help investors to determine whether Immunovia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovia with respect to the benefits of owning Immunovia security.